Saturday 17 October 2026 Export ZURA’s income statement to Excel — free account

Zura Bio Limited

In the quarter to June 2026, EPS fell 23.5% and free cash flow fell 30.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.88 0.40 −9.35%

Follow ZURA

Alert me

Market cap: $410.2M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 12.50

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	1	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 60.29%

Capital & Financial Ratios $m

Market Cap 410.15

Revenue —

Net Income (85.74)

Free Cash Flow (77.63)

Net Debt (205.13)

Current Ratio 12.90

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 2.50

Past 5Y EPS Growth —

This Y EPS Growth 22.42%

Next Y EPS Growth 8.89%

Next Y revenue growth —

Next 5Y EPS Growth 5.23%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 58.31%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	100	176	109	205
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	101	179	112	211

	2023	2024	2025	Q'26
Payables	20	20	12	16
ST’ Debt	—	—	—	—
Other	—	—	—	—
	20	20	12	16

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	(4.85%)	0.00%

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(21)	—	—	—
’25	(11)	(16)	(15)	(22)	(65)
’24	(5)	(7)	(6)	(11)	(28)
’23	(3)	(5)	(3)	(4)	(15)
’22	0	0	(1)	0	(1)
’21	0	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(19)	(21)	—	—	—
’25	(11)	(16)	(15)	(22)	(65)
’24	(10)	(7)	(6)	(11)	(33)
’23	(3)	(11)	(5)	(4)	(23)
’22	(5)	0	(1)	(7)	(13)
’22	—	—	—	—	(1)
’21	0	0	(1)	0	(1)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.22)	(0.21)	—	—	—
’25	(0.19)	(0.17)	(0.21)	(0.49)	(1.06)
’24	(0.02)	(0.17)	(0.26)	(0.08)	(0.60)
’23	(2.76)	(1.31)	(0.18)	2.09	(2.09)
’22	(72.40k)	(9.54)	(2.87)	72.29k	(119.88)
’21	0.00	(0.01)	1.68	0.40	2.07

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	—	—	3.91	2.00	0.97	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	—	—	37.55	6.35	5.62
People
People	Employees	—	—	—	—	—	—	—	15	30	40
	Revenue/emp, $m	—	—	—	—	—	—	—	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	—	—	—	—	—	—	—	—	—	—
	EBT	—	—	—	—	—	7	(27)	(61)	(52)	(69)
	EBT margin, %	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Net income	—	0	—	—	—	7	(27)	(61)	(52)	(69)
	Depreciation	—	—	—	—	—	—	—	—	0	0
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	Earnings	—	—	—	—	—	2.19	(119.88)	(2.09)	(0.60)	(1.06)
	Cash flow	—	—	—	—	—	(0.35)	(5.27)	(0.46)	(0.37)	(0.69)
	Capex	—	—	—	—	—	0.00	(52.63)	(0.24)	(0.07)	0.00
	Free cash flow	—	—	—	—	—	(0.35)	(57.90)	(0.70)	(0.44)	(0.69)
	Book value	—	—	—	—	—	(2.93)	(41.91)	1.84	1.98	1.08
	Shares, m	—	—	—	—	—	3	0	33	75	94
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(1)	(1)	(15)	(28)	(65)
	Capex	—	—	—	—	—	—	(12)	(8)	(5)	0
	Free cash flow	—	—	—	—	—	(1)	(13)	(23)	(33)	(65)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	1	(13)	81	159	100
	Total debt	—	—	—	—	—	—	0	—	—	—
	Net debt	—	—	—	—	—	(1)	(2)	(100)	(176)	(109)
	Shareholders’ equity	—	—	—	—	—	(9)	(10)	61	148	102
Returns, %
Returns, %	ROA	—	—	—	—	—	4.87	(44.43)	(130.52)	(32.38)	(67.71)
	ROIC	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	11.32	207.38	(356.78)	(43.38)	(79.52)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
INDP Indaptus Therapeutics, Inc.	$437.7M	— (loss-making)	—	—	n/m	+52.03% (above 0%: growing)	0.00%	0.00%	Compare
PRTA Prothena Corporation plc	$436.4M	— (loss-making)	188×	−77.15% (below 0%: shrinking)	n/m	+44.64% (above 0%: growing)	100.00%	(2,089.21%)	Compare
DMAC DiaMedica Therapeutics, Inc.	$433.6M	— (loss-making)	— (loss-making)	—	n/m	−6.75% (below 0%: shrinking)	0.00%	0.00%	Compare
PRTCY PureTech Health PLC Sponsored ADR	$424.0M	— (loss-making)	— (loss-making)	−44.60% (below 0%: shrinking)	+66.43% (above 0%: growing)	+19.27% (above 0%: growing)	2.83%	0.00%	Compare
CAPR Capricor Therapeutics, Inc.	$422.7M	— (loss-making)	— (loss-making)	−7.92% (below 0%: shrinking)	n/m	−72.88% (below 0%: shrinking)	100.00%	0.00%	Compare
ASMB Assembly Biosciences, Inc.	$418.8M	19.7×	— (loss-making)	+38.94% (above 0%: growing)	n/m	+7.58% (above 0%: growing)	100.00%	(47.44%)	Compare
TECX Tectonic Therapeutic, Inc.	$416.4M	— (loss-making)	—	—	n/m	−46.69% (below 0%: shrinking)	0.00%	0.00%	Compare
ZURA Zura Bio Limited	$410.2M	— (loss-making)	—	—	n/m	−30.41% (below 0%: shrinking)	—	0.00%
SPRY ARS Pharmaceuticals, Inc.	$404.8M	— (loss-making)	— (loss-making)	+114.15% (above 0%: growing)	n/m	−53.69% (below 0%: shrinking)	61.83%	(182.62%)	Compare
Median of peers	$423.3M	—	—	−7.92%	—	+0.42%	32.33%	0.00%

All 614 Biotechnology stocks →

Zura Bio Limited (ZURA) key facts

Zura Bio Limited (ZURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ZURA traded at $3.88, a market capitalization of $410.2 million.
Return on equity was −79.5% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.